retatrutide phase 2 nejm 2023 obesity trial results GLP-1 Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness Retatrutide hits 28% weight loss

In its Q4 2025 earnings call, Andrew Dudum, co-founder and CEO, noted that the company's "weight loss offering reached $100 million revenue run rate in less than seven months after launch." This speed outstripped its other offerings, which took "three and sometimes even four years to (inaudible) $100 million in annual revenue." This revenue boost occurred despite the significant blowback Hims & Hers faced when it initially announced plans to advertise and sell compounded versions of FDA-approved GLP-1 medications

The action of gremubamab is bivalent in that it targets not only the TS33 but also the adhesin Psl exopolysaccharide in P

Bjorklund has suffered from severe vomiting, stomach pain, gastrointestinal burning, being hospitalized for stomach issues on several occasions including visits to the emergency room, teeth falling out due to excessive vomiting, requiring additional medications to alleviate her excessive vomiting, and throwing up whole food hours after eating, it adds

In ovarian cancer, high GLP1R expression was associated with significantly better survival (HR = 1.27, ogrank p = 0.14)